Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | RAMP1 | O60894 | 3/20 | 0.31 |
| ▸ | CALCRL | Q16602 | 3/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | REN | P00797 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13798451 | 1.00 | DDB1 (0.32) | DDB1CRBNRAMP1CALCRLADRB3 | |
| SCHEMBL13798318 | 0.93 | DDB1 (0.34) | DDB1CRBNRAMP1CALCRLADRB3 | |
| SCHEMBL13798458 | 0.92 | DDB1 (0.34) | DDB1CRBNRAMP1CALCRLADRB3 | |
| SCHEMBL13798448 | 0.92 | DDB1 (0.34) | DDB1CRBNRAMP1CALCRLADRB3 | |
| SCHEMBL13798452 | 0.92 | DDB1 (0.34) | DDB1CRBNRAMP1CALCRLADRB3 | |
| SCHEMBL13798460 | 0.88 | CYP3A4 (0.32) | DDB1CRBNCYP3A4 | |
| SCHEMBL13798459 | 0.88 | CYP3A4 (0.32) | DDB1CRBNCYP3A4 | |
| SCHEMBL13798462 | 0.88 | DDB1 (0.31) | DDB1CRBNRAMP1CALCRL | |
| SCHEMBL497884 | 0.88 | ADRB3 (0.39) | DDB1CRBNADRB3ADRA2BADRA2C | |
| SCHEMBL497883 | 0.88 | ADRB3 (0.39) | DDB1CRBNADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155209-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155209-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | DDB1 499/4885CRBN 1884/4885RAMP1 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.